Abstract: A semiconductor device includes a conductive film containing molybdenum and a metal element. The metal element has a melting point lower than the melting point of molybdenum and forms a complete solid solution with molybdenum. The metal element as a material for composing the conductive film is at least one selected from the group consisting of, for example, titanium, vanadium, and niobium.

Abstract: A compound represented by Formula [3] or a salt thereof and a method of making the in the formula, L3 represents a group represented by Formula [2c] wherein R3c, R4c, R5c and R6c are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; p3 represents an integer of 1 to 3; q3 represents an integer of 0 to 3; and r3 represents an integer of 1 to 6; A1 represents any one of the groups represented by Formulae [4] to [9], wherein * represents a binding position; and R7 represents a carboxyl-protecting group; and m represents an integer of 1 to 3.

Abstract: An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides a compound represented by General Formula [1] (in the formula, R1 represents a halogen atom, an amino group which may be substituted, a C1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R2 represents a hydrogen atom or an amino protecting group; R3 represents a C1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R4 represents a C1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like); or a salt thereof.

Abstract: An object of the present invention is to provide a compound useful as an anti-tumor agent or the like; an intermediate thereof; and a pharmaceutical composition, an anti-tumor agent, and a dihydroorotate dehydrogenase inhibitor, each of which contains the compound.

Abstract: An object of the present invention is to provide a compound useful as an anti-tumor agent or the like, as well as a pharmaceutical composition, an anti-tumor agent, and a dihydroorotate dehydrogenase inhibitor, each of which contains the compound. According to the present invention, a compound represented by General Formula (1) or a salt thereof is provided. In the formula, R1 represents a hydrogen atom or a C1-6 alkyl group; R2, R3, R4, and R5 are the same as or different from each other and each represent a hydrogen atom, a halogen atom, a C1-6 alkyl group which may be substituted, a C1-6 alkoxy group which may be substituted, or the like; R6's are the same as or different from each other and each represent a halogen atom, a C1-6 alkyl group which may be substituted, or a C1-6 alkoxy group which may be substituted; R7 represents a C3-8 cycloalkyl group which may be substituted, or the like; m represents an integer of 0 to 6; and a broken line represents a single bond or a double bond.

Abstract: A thermoplastic polyester resin composition includes a thermoplastic polyester resin (A), and with respect to 100 parts by weight thereof, 1 to 40 parts by weight of an elastomer (B), 15 to 100 parts by weight of a fibrous reinforcing filler (C), 0.4 to 5 parts by weight of a silicone compound (D) and 0.1 to 10 parts by weight of an epoxy compound (E) having an epoxy equivalent of 200 to 400 g/eq. The thermoplastic polyester resin composition has excellent alkaline resistance, hydrolysis resistance, and heat shock resistance, and can form a molded article composed of the thermoplastic polyester resin composition.

Abstract: An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent.

Abstract: An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides a compound represented by General Formula [1] (in the formula, R1 represents a halogen atom, an amino group which may be substituted, a C1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R2 represents a hydrogen atom or an amino protecting group; R3 represents a C1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R4 represents a C1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like); or a salt thereof.

Abstract: A compound represented by Formula [3] or a salt thereof and a method of making the same, in the formula, L3 represents a group represented by Formula [2c] wherein R3c, R4c, R5c, and R6c are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; p3 represents an integer of 1 to 3; q3 represents an integer of 0 to 3; and r3 represents an integer of 1 to 6; A1 represents any one of the groups represented by Formulae [4] to [9], wherein * represents a binding position; and R7 represents a carboxyl-protecting group; and m represents an integer of 1 to 3.

Abstract: Provided are a method for efficiently manufacturing a nitrogen-containing compound, which is used for manufacturing a treatment agent for integrin-related diseases, or a salt thereof and a manufacturing intermediate of the compound or a salt thereof. A method for manufacturing a novel nitrogen-containing compound or a salt thereof includes (1) a step of obtaining a compound represented by Formula [10] or a salt thereof through an amidation reaction; and (2) a step of deprotecting the compound represented by Formula [10] or a salt thereof.

Abstract: A novel amine derivative expressed by general formula (1) (in the formula: G1, G2, and G3 are the same or different and represent CH or a nitrogen atom; R1 represents a chlorine atom, an optionally-substituted C3-8 cycloalkyl group, or the like; R2 represents —COOR5 (in the formula, R5 represents a hydrogen atom or a carboxyl protective group), or the like; R3 represents a hydrogen atom, or the like; and R4 represents an optionally-substituted condensed bicyclic hydrocarbon group, an optionally-substituted bicyclic heterocyclic group, or the like), or a salt thereof is useful in procedures such as the treatment or prevention of conditions related to excessive keratinocyte proliferation.

Abstract: A novel amine derivative expressed by general formula (1) (in the formula: G1, G2, and G3 are the same or different and represent CH or a nitrogen atom; R1 represents a chlorine atom, an optionally-substituted C3-8 cycloalkyl group, or the like; R2 represents —COOR5 (in the formula, R5 represents a hydrogen atom or a carboxyl protective group), or the like; R3 represents a hydrogen atom, or the like; and R4 represents an optionally-substituted condensed bicyclic hydrocarbon group, an optionally-substituted bicyclic heterocyclic group, or the like), or a salt thereof is useful in procedures such as the treatment or prevention of conditions related to excessive keratinocyte proliferation.

Abstract: A pump off control method comprises detecting the speed of the induction motor and an instantaneous value of secondary current of the induction motor. Down stroke time in every cycle of the pump jack is detected. An average value of instantaneous values of the secondary current of the induction motor in the down stroke time in said every cycle is calculated. An average value reference of the secondary current of the induction motor to be compared with calculated average value of the instantaneous values of the secondary current of the induction motor is set. The calculated average value of the instantaneous values of the secondary current is compared with the average value reference after the down stroke end in each cycle. An occurence of pump off is detected if the calculated average value of the instantaneous values is greater than the average value reference.

Abstract: In an inverter controlling method for an induction motor, the slip of the motor is detected and an optimum slip which is dependent on the motor constant and the frequency supplied to the motor providing the highest efficiency is calculated, and a voltage manipulated variable is determined from a comparison of the optimum slip and the slip of the motor, and then the voltage manipulated variable is used to form an output voltage instruction or a magnetic flux instruction so that running of the induction motor is controlled with the slip with which the highest efficiency is provided with respect to load variation and frequency variation.

Abstract: An object of this invention is to provide a high performance and low cost crane rope steadying control method and apparatus for which mechanical or optical swing angle detecting means are not necessary.The invention provides a rope steadying control method for a crane or the like having a trolley driving apparatus for causing a load suspended by a rope of a crane or the like to travel, wherein swinging of a load suspended by a rope is stopped by calculating a swing load signal I.sub.2W * proportional to the rope swing angle and the load by computationally estimating a motor torque estimate signal .tau..sub.M * not including load torque fluctuations caused by swinging of the rope on the basis of gain coefficients and equivalent time constants of the control system and the drive system, and comparing this estimate signal .tau..sub.M * with an actual load torque .tau..sub.M and negatively feeding back to a trolley speed command N.sub.S of the trolley driving apparatus (1) a speed signal N.sub.

Abstract: A control unit for a motor and a control method for it, which are adapted for conducting control at a high speed so that efficiency of the motor by inverter operation of an induction motor is maximum at all times. This unit comprises means (3) for detecting effective power delivered to a motor (14), calculation means (1, 2, 4, 5, 6, 7, 8 16, S.sub.1, S.sub.2, S.sub.3) for calculating, from the detected effective power and frequency (f) of an A.C. voltage delivered to motor (14), supply voltage (V.sub.1) to motor (14) where efficiency of motor (14) becomes maximum, and means (9, 10, 11, 12) for delivering the calculated supply voltage (V.sub.1) to motor (14).

Abstract: When a prime mover (1) is driven, a controller (25) outputs an open-drive signal for bringing an opening/shutting valve (23) into an open position and, upon a control lever (68, etc.) being operated, a hydraulic fluid is supplied from an auxiliary hydraulic pump (7) through pressure reducing valves to driving sectors of directional control valves (8 to 16) for shifting them. A flow rate and a direction of flow of the hydraulic fluid from main hydraulic pumps (3, 4) are thereby adjusted so that actuators (57A, 57B, 57C, 56A, 54) can be each operated at a speed depending on the amount by which the control lever is operated. When one of the actuators (57A, 57B, 57C, 56A, 54) is to be driven when the prime mover (1) is not driven, an open command is selected in a selection command device (24), whereupon the controller (25) outputs the open-drive signal, causing the opening/shutting valve (23) to open a line interconnecting the accumulator (21) and the pressure reducing valve (17), etc.